机译:用Nivolumab处理的非小细胞肺癌患者的响应评估标准与实体瘤中的响应评估标准的一致性:多中心回顾性队列研究
Department of Respiratory Medicine Hyogo Prefectural Amagasaki General Medical Center;
Department of Respiratory Medicine Hyogo Prefectural Amagasaki General Medical Center;
Department of Internal Medicine Japan Community Healthcare Organization Osaka Hospital;
Respiratory Division Department of Internal Medicine Itami City Hospital;
Department of Respiratory Medicine Kobe City Medical Center General Hospital;
Department of Respiratory Medicine Kurashiki Central Hospital;
Department of Respiratory Medicine Iizuka Hospital;
Department of Respiratory Medicine Kobe City Medical Center General Hospital;
Department of Thoracic Oncology Kansai Medical University Hospital;
Immune-related response criteria; Nivolumab; Non-small cell lung cancer; Response Evaluation Criteria in Solid Tumors; Survival;
机译:实体肿瘤版本1.1中的响应评估标准之间的一致性和用Nivolumab处理的非小细胞肺癌患者的免疫相关响应标准:多中心回顾性队列研究
机译:使用TACE(经导管动脉化学栓塞术)治疗的HCC(肝细胞癌)的肿瘤反应评估标准:RECIST(实体瘤反应评估标准)1.1版和mRECIST(改良的RECIST):JIVROSG-0602
机译:使用TACE(经导管动脉化学栓塞)治疗的HCC(肝细胞癌)的肿瘤反应评估标准:RECIST(实体瘤反应评估标准)1.1版和mRECIST(改良的RECIST):JIVROSG-0602
机译:基于CT基肿瘤特征改善对转移性非小细胞肺癌的患者的肿瘤特征预测
机译:评估姑息化疗对非小细胞肺癌的有效性:在安大略省癌症中心接受治疗的患者的IV期研究
机译:使用TACE(经导管动脉化疗栓塞)治疗的HCC(肝细胞癌)的肿瘤反应评估标准:RECIST(实体瘤反应评估标准)1.1版和mRECIST(改良的RECIST):JIVROSG-0602
机译:实体肿瘤1.0响应评价标准对Neoadjuvant化疗的高乳腺癌反应评价MRI响应评价标准响应评价标准的诊断性能比较